TAMPA, Fla.—Due to promising pre-clinical results from its clinical trial at the Cardiovascular Institute of the South, PanGenex is extending its trial to two additional sites. It initiated a 100 patient, placebo-based, double blind clinical trial at the CardioVascular Institute of the South. Early results with only a handful of patients have encouraged the company to expand this trial.
The clinical trial involves a protocol to test its product Calci-CLEAR, a two part system designed to cleanse and remove calcium deposits from soft tissues such as veins and arteries. The study entails baseline coronary arterial calcium (CAC) scans, bone mineral density scans (DXA), and normal blood lipid and inflammatory markers. Under the protocol, patients are screened and then placed on the product for a period of five months. Following the study duration, follow up CAC, DXA and lab tests are collected. Dr. Peter Fail, the principle investigator for the trial, indicated one patient experienced a greater than 50 percent reduction in CAC score following the five months of the study.